Monitoring KAT6A-CREBBP measurable residual disease in t(8;16) therapy-related acute myeloid leukemia. (May 2022)

• Record Type: Journal Article
• Authors: Bhreathnach, Úna; Doherty, Dearbhla; Murphy, Karen; Flynn, Catherine M.; Langabeer, Stephen E.
• Is Part Of: Leukemia research. Volume 116(2022)
• Publication Date: 2022-05
• Subjects: Secondary AML -- t(8 -- 16) -- KAT6A-CREBBP -- Allogeneic stem cell transplantation -- Minimal Residual Disease; Leukemia -- Periodicals; Leukemia -- Periodicals; Leucémie -- Périodiques; Leukemia; Periodicals; Electronic journals; Electronic journals; 616.9941905
• DOI: 10.1016/j.leukres.2022.106823
• Languages: English
• ISSNs: 0145-2126

Abstract

Highlights: Therapy-related AML with the t(8;16) is uncommon and associated with a poor prognosis. Hematopoietic allogeneic stem cell transplantation remains the only curative option. KAT6A-CREBBP transcript identification is necessary for measurable residual disease. RT-qPCR monitoring confirms the efficacy of allogeneic stem cell transplantation. In t(8;16) AML, measurable residual disease peri-transplant may influence prognosis.